About OticPharma
OticPharma is a company based in Yehud (Israel) founded in 2008. OticPharma has raised $4.3 million across 1 funding round from investors including Orbimed. OticPharma has completed 1 acquisition, including Tokai Pharmaceuticals. OticPharma operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Yehud, Israel
- SectorsHealthcare
- Email••••••••
- Website oticpharma.com
- Social LinkedIn
- Total Equity Funding$4.3M (USD)
in 1 rounds
- Latest Funding Round$4.3M (USD), Series A
Feb 2012
- Investors
- Investments & Acquisitions
Funding Insights of OticPharma
OticPharma has successfully raised a total of $4.3M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.3 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.3M
- Total Rounds 1
- Last Round Series A — $4.3M
- First Round $4.3M
(Feb 2012)
- Investors Count 1
All 1 funding rounds of OticPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2012 | $4.3M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in OticPharma
OticPharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for OticPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OticPharma
OticPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tokai Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for prostate cancer and hormonally-driven diseases are developed. | tokaipharmaceuticals.com | Boston, United States | 2004 | Sep 2016 | •••• |
Complete acquisition details for OticPharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of OticPharma
3 dated milestones of OticPharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded OticPharma is founded.
- Funding First funding round of $4.3M.
- Acquisition Acquires Tokai Pharmaceuticals.
Competitors of OticPharma
OticPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| lyratherapeutics.com | 2005 | Watertown, United States | $127.61M | 75 | Small molecule therapeutics for ENT diseases are developed. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. |
Detailed competitors of OticPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to OticPharma
10 companies that operate in the same segment as OticPharma (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OticPharma
OticPharma was founded in 2008 and raised its 1st funding round 4 years after it was founded.
OticPharma is headquartered in Yehud, Israel. It is registered at Yehud, Central District, Israel.
OticPharma is a funded company, having raised a total of $4.3M across 1 funding round to date. The company's 1st funding round was a Series A of $4.3M, raised on Feb 2012.
OticPharma is a clinical-stage company active in the field of ear, nose, and throat disorders. Its current product candidates are based on FoamOtic, a proprietary foam-based drug delivery system that provides sustained exposure of drugs. Its lead product, FoamOtic Externa, is an investigational proprietary, foam-based, extended-release formulation of ciprofloxacin antibiotic, which has been designated for self-administration to potentially treat acute otitis externa in minor and adult patients. It has completed a successful Phase 2 clinical trial with FoamOtic Externa in minor and adult patients with acute otitis externa and is currently planning the Phase 3 program. In November 2015, it acquired Novel Otitis Media Program from Otodyne.
OticPharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
OticPharma has made 1 acquisition, including Tokai Pharmaceuticals.
OticPharma has 1 investor. Key investors include Orbimed.